New study shows Xeloda after surgery significantly increases number of patients free of colon cancer


Oral therapy now anticipated to replace intravenous chemotherapy

New Orleans (June 6, 2004) - New data from the X-ACT trial (Xeloda in Adjuvant Colon Cancer Therapy), involving almost 2,000 patients, was presented today at the American Society of Clinical Oncology (ASCO), demonstrating that Xeloda (capecitabine), a targeted oral chemotherapy, should replace the current standard therapy known as the Mayo Clinic regimen (intravenous 5-FU/LV) due to its superior efficacy and safety.

The global study successfully met its primary endpoint of demonstrating at least equivalent disease free survival. More remarkably, the study highlights that Xeloda reduces the risk of tumours coming back (relapse-free survival) by an impressive 14% compared to i.v. 5-FU/LV. This means that, each year, if treated with Xeloda, nearly 4,000 additional patients worldwide would not hear the dreaded words "Your cancer has come back."

"This data shows the significant potential of Xeloda to cure more patients with early stage colon cancer," said Professor Jim Cassidy, Cancer Research UK Professor of Oncology and Chair of Medical Oncology, Beatson Oncology Centre, and University of Glasgow in Glasgow, Scotland, presenter of the X-ACT data at ASCO. He added, "The results of the trial further justify the ongoing and planned adjuvant studies of Xeloda in combination with other chemotherapies and targeted therapy such as Avastin."

Stefan Manth, Roche's Business Director in Oncology said, "The results of this trial offer new hope to patients and their families and represent a significant opportunity for Roche. We presently support studies of Xeloda on a global level enrolling over 6,000 patients per year which will further establish the importance of Xeloda in the fight against cancer."

In 2000, colorectal cancer was the third most commonly reported cancer with 945,000 new cases worldwide. It is estimated that over 50% of people diagnosed with colorectal cancer will die of the disease, and it is one of the most common cancers in developed countries1. Chemotherapy following surgery (adjuvant therapy) is one of the most common treatment approaches in patients diagnosed with the disease.

Source: Eurekalert & others

Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
    Published on All rights reserved.